SANFORD GUIDE ANTIMICROBIAL

Drug Shortages

Prep Started At Notes
Oral susp, 1 gm packets 2024-11-20

Usage and Dosing

  • Azithromycin is a macrolide antibiotic used to treat a wide range of clinical conditions, including bacterial conjunctivitis, upper respiratory tract bacterial infections, some patients with bacterial community-acquired pneumonia (CAP), disseminated Mycobacterium avium complex (MAC), pertussis, Chlamydia, gonococcal STDs, and cat scratch disease.
  • Mechanism of resistance: Methylation of ribosomal target and activation of efflux pump.
  • Available in multiple pharmaceutical preparations (see Pharmacology).
  • Evaluate risk of prolongation of QTc before prescribing; details under adverse effects

Adult Dose

Bacterial conjunctivitis 1% oph solution: 1 drop bid x2 days,
then 1 drop once daily x 5 days
Respiratory tract
(mild/moderate infection)
500 mg po day 1,
then 250 mg po once daily, days 2-5
Community-acquired pneumonia (CAP) 500 mg IV once daily
(often combined with beta-lactam)
Chancroid 1 gm po single dose
C. trachomatis 1 gm po single dose
N. gonorrhoeae 2 gm po single dose

Pediatric Dose

Dose (Age >28 Days) See syndrome pages for dosing details
Oral: 5-12 mg/kg/day (once daily)
IV: 5-10 mg/kg/day (once daily)
Max/Day -

Renal Adjustment

  • Body weight and Creatinine Clearance calculations
  • CrCl = Creatinine clearance (mL/min)
  • CAPD = Continuous Ambulatory Peritoneal Dialysis
  • CRRT = Continuous Renal Replacement Therapy
  • AD = after hemodialysis
  • SLED = sustained low efficiency dialysis
    Half-life, hrs (renal function normal) 68
    Half-life, hrs (ESRD) Unchanged
    Dose (renal function normal) 250-500 mg IV/po q24h
    CrCl or eGFR No dosage adjustment for renal impairment
    Hemodialysis No dosage adjustment
    CAPD No dosage adjustment
    CRRT No dosage adjustment
    SLED No data

    Hepatic Adjustment

      Mild impairment (Child-Pugh Class A) No dosage adjustment
      Moderate impairment (Child-Pugh Class B) No dosage adjustment
      Severe impairment (Child-Pugh Class C) No dosage adjustment

      Adverse Effects

      • Treatment stopped due to adverse effects (1%), rash (rare), neutropenia (rare), thrombocytopenia (rare), nausea/vomiting (3%), diarrhea (5%), increased LFTs (rare), increased BUN/Creatinine (rare).
      • Variety of other laboratory abnormalities (e.g., lymphopenia, eosinophilia, electrolytes and liver function abnormalities), which may or may not be drug related, have been reported at a frequency of 1% or less.
      • Transient reversible hearing loss from Azithromycin (J Otolaryngol 36:257, 2007).
      • QTc interval prolongation: Any of the macrolides (Azithromycin, Clarithromycin, and Erythromycin) have the potential of increasing the QTc interval and predispose to ventricular tachycardia.
        • QTc prolongation may be congenital or acquired (N Engl J Med 358:169, 2008). Variable prevalence of mutations associated with long QT: 11% in Denmark vs. 20% in New Zealand or Minnesota (J Cardiovasc Electrophysiol 23:1092, 2012).
        • In retrospective controlled study from Tennessee, 5 days of Azithromycin increased the risk of cardiovascular death (hazard ratio 2.88, p 0.001); compared to Amoxicillin, estimated 47 additional cardiovascular deaths per 1 million courses of therapy (N Engl J Med 366:1881, 2012). Subsequent larger study in generally younger population from Denmark showed CV mortality in Azithromycin recipients was only 15.4/million courses vs. 85.2/million courses in the Tennessee study (N Engl J Med 368:1704, 2013; N Engl J Med 368:1665, 2013).

        • Risk of ventricular arrhythmia and/or cardiac death studied in 2 million Taiwanese outpatients treated within 7 days with amox/clav, oral FQ, or oral macrolide (Azithromycin/Clarithromycin). Although the number of events was low, compared to Amoxicillin-clavulanate, the highest propensity score adjusted odds ratios were 2.74 for Moxifloxacin, and 3.4 for Azithromycin (Clin Infect Dis 60: 566, 2015).
        • Hence, Azithromycin may increase risk of CV death in patients with congenital or acquired cardiovascular disease risk factors. Caution indicated in patients with history of unexplained syncope, family history of unexplained sudden cardiac death, known electrolyte abnormalities, or the need for concomitant administration of other drugs known to potentially prolong the QTc.

        • Prolonged QTc defined as > 470 ms for men; > 480 ms for women, and > 500 ms for either men or women.
        • Review with balance of benefits vs risk see Am J Med 128: 1362.e1, 2015.

      Pregnancy Risk

      FDA Risk Category 1 Humans: no evidence of toxicity.
      Animals: some evidence of decreased viability and delayed development in rats.
      Use during Lactation Safe, monitor infant for GI toxicity

      Footnotes:

      1 :

      Capital letter = Old FDA risk category; Text = New FDA risk category

      Antimicrobial Spectrum

      Agent is a first line therapy: reliably active in vitro, clinically effective, guideline recommended, recommended as a primary or acceptable alternative agent in the Sanford Guide. See pathogen page for specific recommendations.

      Alternative + ( 13 )

      Agent is a potential alternative agent (active in vitro, possesses class activity comparable to known effective agents or a therapeutically interchangeable agents and hence likely to be clinically effective, but second line due to overly broad spectrum, toxicity, limited clinical experience, or paucity of direct evidence of effectiveness).

      • Mycoplasma species are generally susceptible to azithromycin and other macrolides. The exception is Mycoplasma hominis which is resistant to macrolides.

      Pharmacology

      PK/PD Index 24-hr AUC/MIC
      Pharmaceutical Preparations Tab (250, 500, 600 mg)
      Oral susp (1 gm pkt)
      Oral susp (100 mg/5 mL, 200 mg/5 mL)
      1% oph soln
      Injection
      Food Rec (PO Drugs) 1 All preps ± food
      Oral Absorption (%) 37
      Tmax (hr) po 2.5
      Peak Serum Conc (µg/mL) 2 0.4 (500 mg po, SD)
      3.6 (500 mg IV, SD)
      Peak Urine Conc (µg/mL) No data
      Protein Binding (%) 7-51
      Volume of Distribution (Vd) 3 31.1-33.3 L/kg
      Avg Serum T½ (hr) 4 68
      Elimination Biliary
      Bile Penetration (%) 5 High
      CSF/blood (%) 6 No data
      Therapeutic Levels in CSF 7 No data
      AUC (µg*hr/mL) 8 4.3 (500 mg po, 0-inf)
      9.6 (500 mg IV, 0-24 hr, pre-SS)

      Footnotes:

      1 : Refers to adult oral preparations unless otherwise noted; + food = take with food, no food = take without food, ± food = take with or without food
      2 : SD = after a single dose, SS = at steady state
      3 : V/F = Vd/oral bioavailability; Vss = Vd at steady state; Vss/F = Vd at steady state/oral bioavailability
      4 : Assumes CrCl >80 mL/min
      5 : (Peak concentration in bile/peak concentration in serum) x 100. If blank, no data.
      6 : CSF concentrations with inflammation.
      7 : Judgment based on drug dose and organism susceptibility. CSF concentration ideally ≥10x MIC.
      8 : AUC = area under serum concentration vs. time curve. KEY: 0-inf = AUC 0 to infinity; 0-xh = AUC 0 to x hours.

      Enzyme- Transporter-mediated Interactions

      CYP450s that drug is a substrate for: -
      Transporters that drug is a substrate for: PGP
      UGTs that drug is a substrate for: -
      CYP450s inhibited by drug: -
      Transporters inhibited by drug: PGP (weak)
      UGTs inhibited by drug: -
      CYP450s induced by drug: -
      Transporters induced by drug: -
      UGTs induced by drug: -
      Impact on serum drug concentrations 1 mild ↑

      Footnotes:

      1 :

      Refers to serum concentrations of companion drugs that may be affected by the listed antimicrobial. ↑=increase, ↓=decrease.

      Major Drug Interactions

      Drug Effect on concentration (or other) Suggested management
      Amiodarone ↑QT interval Monitor or avoid
      Apixaban ↑apixaban Monitor or avoid
      Betrixaban ↑betrixaban Monitor or avoid
      Cyclosporine ↑cyclosporine Monitor or avoid
      Dabigatran ↑dabigatran Monitor or avoid
      Digoxin ↑digoxin Monitor, adjust dosage
      Dofetilide ↑QT interval Monitor or avoid
      Edoxaban ↑edoxaban Monitor or avoid
      Everolimus ↑everolimus Monitor or avoid
      Nelfinavir ↑azithromycin Monitor
      Procainamide ↑QT interval Monitor or avoid
      Quinidine ↑QT interval Monitor or avoid
      Rivaroxaban ↑rivaroxaban Monitor or avoid
      Sirolimus ↑sirolimus Monitor or avoid
      Sotalol ↑QT interval Monitor or avoid
      Tacrolimus ↑tacrolimus Monitor or avoid

       

      On This Page

      Magnifying Glass Icon Delete Search Text Icon

      No alert to display

      • Filter Type of Content
      Advanced Search Features:

      Try searching using "AND" "OR" or "NOT" to find what you need faster. Watch our boolean operators video for an example

      No Results Yet Icon No Results Use the search bar above to find what you're looking for.